Deutsche Bank Aktiengesellschaft Increases Pediatrix Medical Group (NYSE:MD) Price Target to $15.00

Pediatrix Medical Group (NYSE:MD) had its price objective boosted by analysts at Deutsche Bank Aktiengesellschaft from $9.00 to $15.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft’s price objective would suggest a potential upside of 1.63% from the company’s previous close.

A number of other equities research analysts also recently issued reports on MD. UBS Group upped their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research report on Friday, August 9th. StockNews.com raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. Mizuho increased their price objective on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Monday. Jefferies Financial Group upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and upped their target price for the stock from $8.00 to $14.00 in a research report on Thursday, September 26th. Finally, Truist Financial raised their target price on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Pediatrix Medical Group currently has a consensus rating of “Hold” and an average target price of $14.10.

Pediatrix Medical Group Trading Down 3.0 %

NYSE:MD traded down $0.45 during trading hours on Monday, hitting $14.76. 501,476 shares of the stock were exchanged, compared to its average volume of 869,672. The company’s 50 day moving average is $11.62 and its two-hundred day moving average is $9.41. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.87. The company has a market capitalization of $1.27 billion, a P/E ratio of -4.82, a price-to-earnings-growth ratio of 1.91 and a beta of 1.55. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $15.42.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. The firm had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The business’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the business posted $0.29 earnings per share. On average, sell-side analysts anticipate that Pediatrix Medical Group will post 1.19 earnings per share for the current fiscal year.

Insider Buying and Selling at Pediatrix Medical Group

In other news, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the transaction, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at $1,834,310.79. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the sale, the director now directly owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO James D. Swift sold 11,100 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the transaction, the chief executive officer now directly owns 170,001 shares in the company, valued at $1,834,310.79. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 68,100 shares of company stock valued at $701,889. 2.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

Several hedge funds and other institutional investors have recently modified their holdings of MD. Rubric Capital Management LP boosted its position in shares of Pediatrix Medical Group by 797.0% during the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after buying an additional 7,241,400 shares during the period. Dana Investment Advisors Inc. grew its stake in shares of Pediatrix Medical Group by 80.3% in the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after acquiring an additional 455,785 shares in the last quarter. Boston Partners grew its stake in Pediatrix Medical Group by 34.0% during the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after buying an additional 453,254 shares in the last quarter. Cubist Systematic Strategies LLC boosted its stake in shares of Pediatrix Medical Group by 639.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock valued at $2,192,000 after purchasing an additional 251,072 shares in the last quarter. Finally, ClariVest Asset Management LLC acquired a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at approximately $1,721,000. Institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.